Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells

Molecular Cancer Therapeutics

Volumn 6, Issue 3, 2007, Pages 967-978

  Mimeault, Murielle ^a   Johansson, Sonny L ^a,b   Vankatraman, Ganesh ^a   Moore, Eric ^a   Henichart, Jean Pierre ^c   Depreux, Patrick ^c   Lin, Ming Fong ^a,b   Batra, Surinder K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CASPASE; CERAMIDE; CYCLOPAMINE; CYTOCHROME C; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MATRIGEL; SONIC HEDGEHOG PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METASTASIS POTENTIAL; MITOCHONDRION; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CYTOCHROMES C; HEDGEHOG PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEOPLASM INVASIVENESS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TAXOIDS; TUMOR CELLS, CULTURED; VERATRUM ALKALOIDS;

EID: 34147147058     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0648     Document Type: Article

References (70)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 2006;27:1-22.
3. Clarke NW. Management of the spectrum of hormone refractory prostate cancer. Eur Urol 2006;50:428-38.
4. Berry W, Eisenberger M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 2005;10: 30-9.
5. Arlen PM, Gulley JL. Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer. Future Oncol 2005;1: 19-22.
6. Di Lorenzo G, De PS. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Int J Immunopathol Pharmacol 2006;19:11-34.
7. Winquist E, Waldron T, Berry S, Ernst DS, Hotte S, Lukka H. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. BMC Cancer 2006;6:112.
8. Sharifi N, Kawasaki BT, Hurt EM, Farrar WL. Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol Ther 2006;5:901-6.
9. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65:10946-51.
10. Collins AT, Maitland NJ. Prostate cancer stem cells. Eur J Cancer 2006;42:1213-8.
11. Mimeault M, Batra SK. Recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells 2006;24: 2319-45.
12. Kasper S, Cookson MS. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 2006;33:201-10.
13. Lam JS, Reiter RE. Stem cells in prostate and prostate cancer development. Urol Oncol 2006;24:131-40.
14. Laber DA, Glisson SD, Hargis JB, et al. A phase II study of higher dose docetaxel in androgen-independent prostate cancer. Am J Clin Oncol 2006;29:389-94.
15. Sirotnak FM, She Y, Lee F, Chen J, Scher HI. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 2002;8:3870-6.
16. Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A, Bologna M. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol 2003; 129:165-74.
17. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003;9:1200-10.
18. Festuccia C, Angelucci A, Gravina GL, et al. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost 2005;93:964-75.
19. Mimeault M, Pommery N, Henichart JP. Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines. Int J Cancer 2003;106:116-24.
20. Mimeault M, Jouy N, Depreux P, Henichart JP. Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines. Prostate 2005;62:187-99.
21. Sgambato A, Camerini A, Faraglia B, et al. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. J Cell Physiol 2004;201:97-105.
22. Mimeault M, Moore E, Moniaux N, et al. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int J Cancer 2006;118:1022-31.
23. Angelucci A, Gravina GL, Rucci N, et al. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 2006;13:197-210.
24. Karhadkar SS, Bova GS, Abdallah N, et al. Hedgehog signalling in prostate regeneration, neoplasia, and metastasis. Nature 2004;431: 707-12.
25. Sumitomo M, Ohba M, Asakuma J, et al. Protein kinase Cδ amplifies ceramide formation via mitochondrial signaling in prostate cancer cells. J Clin Invest 2002;109:827-36.
26. Pchejetski D, Golzio M, Bonhoure E, et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 2005;65:11667-75.
27. Eto M, Bennouna J, Hunter OC, Lotze MT, Amoscato AA. Importance of C16 ceramide accumulation during apoptosis in prostate cancer cells. Int J Urol 2006;13:148-56.
28. Mimeault M, Pommery N, Wattez N, Bailly C, Henichart JP. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 2003;56:1-12.
29. Truman JP, Gueven N, Lavin M, et al. Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis. J Biol Chem 2005;280:23262-72.
30. Samsel L, Zaidel G, Drumgoole HM, et al. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 2004;58:382-93.
31. Mimeault M, Venkatraman G, Johansson SL, et al. Novel combination therapy against metastatic and androgen-independent prostate cancer by using a combination of gefitinib, tamoxifen, and etoposide. Int J Cancer 2007;120:160-9.
32. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002;50:222-35.
33. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911-4.
34. Hirst SJ, Barnes PJ, Twort CH. Quantifying proliferation of cultured human and rabbit airway smooth muscle cells in response to serum and platelet-derived growth factor. Am J Respir Cell Mol Biol 1992;7:574-81.
35. Zamzami N, Marchetti P, Castedo M, et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995;182:367-77.
36. Mimeault M. New advances on structural and biological functions of ceramide in apoptotic/necrotic cell death and cancer. FEBS Lett 2002;530: 9-16.
37. Fan CM, Porter JA, Chiang C, Chang DT, Beachy PA, Tessier-Lavigne M. Long-range sclerotome induction by sonic hedgehog: direct role of the amino-terminal cleavage product and modulation by the cyclic AMP signaling pathway. Cell 1995;8:457-65.
38. Torroja C, Gorfinkiel N, Guerrero I. Mechanisms of Hedgehog gradient formation and interpretation. J Neurobiol 2005;64:334-56.
39. Chen MH, Li YJ, Kawakami T, Xu SM, Chuang PT. Palmitoylation is required for the production of a soluble multimeric Hedgehog protein complex and long-range signaling in vertebrates. Genes Dev 2004;18: 641-59.
40. Miura GI, Treisman JE. Lipid modification of secreted signaling proteins. Cell Cycle 2006;5:1184-8.
41. Fan L, Pepicelli CV, Dibble CC, et al. Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology 2004;145:3961-70.
42. Sanchez P, Hernandez AM, Stecca B, et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A 2004;101:12561-6.
43. Sheng T, Li C, Zhang X, et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer 2004;3:29.
44. Chen BY, Lin DP, Liu JY, et al. A mouse prostate cancer model induced by Hedgehog overexpression. J Biomed Sci 2006;13:373-84.
45. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 2004;90:449-54.
46. Di Lorenzo G, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-44.
47. Schafer W, Funke PJ, Kunde D, Rausch U, Wennemuth G, Stutzer H. Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: correlation with clinical data of long-term observations. J Urol 2006; 176:532-7.
48. Festuccia C, Muzi P, Millimaggi D, et al. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocr Relat Cancer 2005;12:983-98.
49. Rizzo S, Attard G, Hudson DL. Prostate epithelial stem cells. Cell Prolif 2005;38:363-74.
50. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res 2006;66:1883-90.
51. Koeneman KS. Prostate cancer stem cells, telomerase biology, epigenetic modifiers, and molecular systemic therapy for the androgen-independent lethal phenotype. Urol Oncol 2006;24:119-21.
52. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A 2006;103:1480-5.
53. Lawson DA, Xin L, Lukacs R, Xu Q, Cheng D, Witte ON. Prostate stem cells and prostate cancer. Cold Spring Herb Symp Quant Biol 2005; 70:187-96.
54. Googe PB, McGinley KM, Fitzgibbon JF. Anticytokeratin antibody 34β E12 staining in prostate carcinoma. Am J Clin Pathol 1997;107: 219-23.
55. Yang XJ, Lecksell K, Gaudin P, Epstein JI. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. Am J Surg Pathol 1999;23:147-52.
56. van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001;195:563-70.
57. + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25: 1696-708.
58. Tang DG, Patrawala L, Calhoun T, et al. Prostate cancer stem/ progenitor cells: identification, characterization, and implications. Mol Carcinog 2007;46:1-14.
59. van Bokhoven A, Varella-Garcia M, Korch C, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003; 57:205-25.
60. Zellweger T, Ninck C, Bloch M, et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005;113:619-28.
61. Bartlett JM, Brawley D, Grigor K, Munro AF, Dunne B, Edwards J. Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. J Pathol 2005;205:522-9.
62. Gil-Diez de MS, Salomon L, Colombel M, et al. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol 1998;29:1005-12.
63. Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11:5233-40.
64. Garzotto M, Myrthue A, Higano CS, Beer TM. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol 2006;24:254-9.
65. Koukourakis MI, Touloupidis S. External beam radiotherapy for prostate cancer: current position and trends. Anticancer Res 2006;26: 485-94.
66. Winquist E. Chemotherapy for non-hormone refractory prostate cancer. Can J Urol 2006;13:67-70.
67. Sugita S, Kawashima H, Tanaka T, Kurisu T, Sugimura K, Nakatani T. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: ligand-independent activation of the N-terminal domain of the androgen receptor. Oncol Rep 2004;11:1273-9.
68. Festuccia C, Gravina GL, Angelucci A, et al. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int J Cancer 2005;115:630-40.
69. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-92.
70. Penne K, Bohlin C, Schneider S, Allen D. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. Cancer Nurs 2005;28:481-6.